CJC-1295 vs Ipamorelin: Research Comparison
CJC-1295 is a GHRH analog that activates the pituitary GHRH receptor to amplify the amplitude of GH secretion; Ipamorelin is a selective GHRP that activates the ghrelin receptor (GHSR-1a) to trigger a GH pulse and suppress somatostatin. They operate on entirely different receptor pathways — making their combination synergistic rather than redundant. Researchers consistently study the CJC-1295 and Ipamorelin stack as the most selective and well-characterized GH secretagogue pairing.
Quick Reference Table
| Attribute | CJC-1295 (no DAC) | Ipamorelin |
|---|---|---|
| Type | GHRH analog (Mod GRF 1-29) | Synthetic pentapeptide GHRP (ghrelin mimetic) |
| Mechanism | GHRH receptor agonist — amplifies GH release amplitude | Ghrelin receptor agonist (GHSR-1a) — triggers GH pulse, suppresses somatostatin |
| Category | Growth Hormone secretagogue | Growth Hormone secretagogue |
| Route | Subcutaneous injection | Subcutaneous injection |
| Half-life | Approximately 30 min (no DAC); 8–10 days (with DAC) | Approximately 2 hours |
| Common Research Dose | 100–200 mcg per injection, 2 times daily | 100–300 mcg per injection, 1–3 times daily |
| Vial Size | 2 mg (typical) | 5 mg (typical) |
CJC-1295 — Research Overview
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), modified at four positions to extend its half-life beyond the 7-minute window of native GHRH. The version without DAC (Drug Affinity Complex), commonly called Modified GRF 1-29 or Mod GRF 1-29, retains a half-life of approximately 30 minutes — long enough to amplify a natural GH pulse but not long enough to produce the continuous, blunted-pulse GH secretion sometimes associated with the DAC version. CJC-1295 with DAC extends the half-life to 8–10 days by covalently binding to circulating albumin, producing sustained GH elevation and downstream IGF-1 increases.
Preclinical research in rats and early human pharmacokinetic studies established that CJC-1295 with DAC, administered at 1–2 mg weekly, produced mean GH increases of 2–10 fold and sustained IGF-1 elevations of approximately 20–40% over multiple weeks. Researchers studying anabolic effects, body composition, and sleep quality typically prefer the without-DAC version to preserve pulsatility; those interested in sustained IGF-1 elevation may investigate the DAC formulation.
Ipamorelin — Research Overview
Ipamorelin is a synthetic pentapeptide (5 amino acids) classified as a growth hormone-releasing peptide (GHRP) and selective ghrelin receptor agonist. Its mechanism differs fundamentally from GHRH analogs: rather than stimulating the GHRH receptor, Ipamorelin activates GHSR-1a (the ghrelin receptor), which triggers GH pulse release and simultaneously suppresses somatostatin — the endogenous inhibitor of GH secretion. The combination of pulse induction and somatostatin suppression makes Ipamorelin highly effective at producing robust, physiologically appropriate GH spikes.
A key research advantage of Ipamorelin over older GHRPs (GHRP-2, GHRP-6, and hexarelin) is selectivity: at research doses, Ipamorelin produces negligible elevation in cortisol and prolactin. Older GHRPs stimulated adrenocorticotropic hormone (ACTH) and cortisol release at similar doses, making them less suitable for research protocols where glucocorticoid side effects are a confounding variable. Ipamorelin is typically administered at 100–300 mcg per injection, one to three times daily, with the bedtime dose considered most impactful.
Key Differences
- 1Receptor system: CJC-1295 targets GHRH receptors on pituitary somatotrophs; Ipamorelin targets GHSR-1a (ghrelin receptors) — entirely different signal pathways.
- 2GH secretion pattern: CJC-1295 amplifies the amplitude of a GH pulse; Ipamorelin initiates the pulse and suppresses somatostatin to prolong it.
- 3Selectivity: Ipamorelin is selective for GH release with minimal cortisol and prolactin elevation; some older GHRPs raise cortisol significantly.
- 4Half-life: CJC-1295 without DAC has a half-life of approximately 30 minutes; Ipamorelin approximately 2 hours; CJC-1295 with DAC extends to 8–10 days.
- 5IGF-1 effects: CJC-1295 (especially with DAC) produces sustained IGF-1 elevation; Ipamorelin alone produces transient GH spikes less likely to sustain IGF-1 increases.
- 6Synergy when combined: because their pathways are distinct and complementary, the combination produces GH secretion approximately 8-fold greater in area-under-curve than either compound alone in rat studies.
When Researchers Choose CJC-1295 vs Ipamorelin
| Research Context | CJC-1295 | Ipamorelin |
|---|---|---|
| Studying isolated GHRH receptor signaling | Preferred — selective GHRH agonist | Not applicable — ghrelin receptor pathway |
| Studying isolated ghrelin receptor signaling | Not applicable | Preferred — selective GHSR-1a agonist |
| Maximizing GH secretion (both pathways) | GHRH axis component of the stack | GHRP axis component of the stack — used together |
| Avoiding cortisol and prolactin elevation | No cortisol effect as a GHRH analog | Preferred GHRP — minimal cortisol and prolactin signal |
| Sustained IGF-1 elevation research | CJC-1295 with DAC preferred (sustained GH bleed) | Less effective alone for sustained IGF-1 increases |
| Preserving pulsatile GH physiology | CJC-1295 without DAC (Mod GRF 1-29) | Natural pulse pattern — compatible with either CJC form |
Can They Be Stacked Together?
All content on this page is produced for educational and research purposes only. CJC-1295 and Ipamorelin are research peptides not approved by any regulatory agency for human use. Nothing here constitutes medical advice.
CJC-1295 vs Ipamorelin FAQ
What is the fundamental difference between CJC-1295 and Ipamorelin?+
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to release GH through GHRH receptor activation — producing a sustained elevation in GH. Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that mimics ghrelin, triggering a distinct, pulse-like GH release via the ghrelin receptor (GHSR-1a). They act on entirely different receptor systems and are the most synergistic GH secretagogue pair studied in preclinical research.
What does 'DAC' mean in CJC-1295 with DAC vs without DAC?+
DAC stands for Drug Affinity Complex — a modification that allows CJC-1295 to bind covalently to albumin in the blood, extending its half-life from approximately 30 minutes (without DAC) to 8–10 days (with DAC). CJC-1295 without DAC requires twice-daily subcutaneous injection to maintain activity; CJC-1295 with DAC needs only once-weekly dosing. Without DAC is sometimes called 'Modified GRF 1-29' or 'Mod GRF 1-29'.
Why are CJC-1295 and Ipamorelin considered synergistic?+
Synergy arises from pathway complementarity. CJC-1295 drives the GHRH axis to amplify the amplitude of GH release; Ipamorelin drives the ghrelin receptor to trigger the GH pulse itself and simultaneously suppresses somatostatin (the GH inhibitor). Together they produce a GH secretion event that is larger in amplitude and longer in duration than either peptide produces alone. Research in rats demonstrates GH area-under-curve approximately 8-fold greater for the combination than for either compound individually.
Why is Ipamorelin considered 'clean' compared to other GHRPs?+
Older GHRPs such as GHRP-2 and GHRP-6 stimulate GH but also significantly elevate cortisol and prolactin — hormones that researchers generally wish to avoid elevating. Ipamorelin is selective: it raises GH with minimal impact on cortisol and prolactin at research doses, making it the preferred GHRP in most contemporary stacks.
How is the CJC-1295 / Ipamorelin stack typically dosed in research?+
Using CJC-1295 without DAC (Mod GRF 1-29) plus Ipamorelin, researchers commonly administer 100 mcg of each compound per injection, two to three times daily, typically around meals and at bedtime — the bedtime dose is considered most important to align with endogenous pulsatile GH secretion. When using CJC-1295 with DAC, the CJC component is dosed at 1–2 mg once weekly while Ipamorelin continues on its own daily schedule.
Do CJC-1295 and Ipamorelin increase IGF-1 levels?+
Preclinical and some human research data indicate that sustained GH elevation produced by CJC-1295 (particularly the DAC form) leads to downstream increases in IGF-1 (insulin-like growth factor 1) produced by the liver. Ipamorelin alone in short pulses produces transient GH elevations less likely to produce sustained IGF-1 rises. The combination appears to drive meaningful IGF-1 elevation, which researchers associate with its anabolic and tissue-repair research effects.
CJC-1295 Dose Calculator
Use the calculator below to convert your CJC-1295 vial size and bacteriostatic water volume into a per-unit insulin syringe draw — for research and educational purposes only.
Educational use only. This calculator performs unit math on the values you provide and is not a substitute for medical advice. Verify every calculation independently.
Result
Numbers are computed from your inputs. Verify all calculations independently. Educational use only.